



News Release

Transfer of BioWa's "External Innovation Engine" In-Licensing Activities to Kyowa Hakko Kirin California

La Jolla, California, February 16, 2015 – BioWa, Inc. (President and CEO: Yasunori Yamaguchi, Ph.D.; headquartered in La Jolla, California, "BioWa"), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (President & CEO: Nobuo Hanai, Ph.D.; headquartered in Tokyo, Japan: "Kyowa Hakko Kirin"), announced today the transfer of its in-licensing activities to its sister company, Kyowa Hakko Kirin California (President: Yasunori Yamaguchi, Ph.D; headquartered in La Jolla, California, "KKC"), which is also a wholly owned subsidiary of Kyowa Hakko Kirin.

With this business transition, KKC takes over BioWa's in-licensing activities which is also known as "External Innovation Engine (EIE)", to serve as an oversea window for the Research and Development Division of Kyowa Hakko Kirin and actively seek external opportunities in products at discovery through pre-clinical stages and in novel innovative technologies to enrich Kyowa Hakko Kirin's research product pipeline in the areas of oncology, immunology (inflammations, autoimmune diseases), nephrology and central nervous system. KKC will also consider strategic collaborations and/or partnerships with pharmaceuticals, biotech and academia. BioWa will continue partnering activities of Kyowa Hakko Kirin's proprietary antibody technologies, POTELLIGENT® and COMPLEGENT®, which BioWa has been engaging in as the exclusive licensor for over ten years since its establishment in 2003.

"It is the strategic decision to transfer BioWa's EIE function to KKC, as an arm of Research and Development Division of Kyowa Hakko Kirin, to further accelerate in-licensing activities and enrich Kyowa Hakko Kirin's research pipeline", said Yasunori Yamaguchi Ph.D., President and CEO of BioWa. "BioWa, as a business development arm of Kyowa Hakko Kirin, will be focusing on partnering activities of POTELLIGENT® and COMPLEGENT® technologies to provide additional value to our partner's therapeutic antibodies and contribute to healthy, fulfilling and comfortable lives."

For more information on BioWa, POTELLIGENT® and COMPLEGENT® technologies, please contact us using the Licensing Contact Form on our website (<http://www.kyowa-kirin.com/biowa>)

For more information on Kyowa Hakko Kirin California, please visit its website at <http://www.kyowa-kirin.com/kkc>

Contact:

BioWa, Inc.

9420 Athena Circle

La Jolla, CA 92037

858-952-7200

<http://www.kyowa-kirin.com/biowa>